Skip to main content
OpenTrials
Completed

NCT Number: NCT03052309

BIOLUX P-III BENELUX All-Comers Registry

The purpose of the BIOLUX P-III BENELUX Registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Ballon when used in daily clinical practice for the treatment of isolated atherosclerotic lesion (vessel narrowing) in popliteal arteries

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ziekenhuis Oost Limburg Genk, Genk, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years or minimum age as required by local regulations
  • Subject must be willing to sign a Patient Data Release Form (PDRF) or Patient Informed Consent (PIC) where applicable
  • Lesion(s) in the popliteal arteries suitable for endovascular treatment, treated with or scheduled to be treated with the Passeo-18 Lux drug coated balloon.
  • Isolated popliteal artery lesion: at least 2 cm of healthy segment between lesion(s) in the popliteal artery and lesion(s) in distal superficial femoral artery
  • Inflow free from flow-limiting lesion. Patients with flow-limiting inflow lesions (> 50% stenosis) can be included if lesion(s) have been treated successfully before or during the index procedure, with a maximum residual stenosis of 30% per visual assessment
  • At least one native artery with direct outflow artery to the foot
  • Rutherford classification 2-5
  • Patient with bypass surgery in the same limb can be enrolled if there is at least 2 cm healthy segment between popliteal artery and anastomosis

Exclusion criteria

  • Life expectancy ≤ 1 year
  • Rutherford classification 6
  • Lesion involving the superficial femoral artery (arterial intersection with the femur in an anteroposterior view) or extending in infra-popliteal arteries (origin of the anterior tibial artery or tibioperoneal trunk)
  • Aneurysm at the level of the popliteal artery
  • Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations)
  • Intraprocedural decision not to proceed with the Passeo18 Lux DCB for any reason not related to the device (for instance blood flow limiting dissection after predilatation)
  • Subject is currently participating in another investigational drug or device study that has not reached its primary endpoint yet
  • Subject is pregnant or planning to become pregnant during the course of the study

Treatment and study plan

Passeo-18 Lux DCB

Device

The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)

Primary outcomes

  1. Freedom from Major Adverse Events (MAE)

    Time frame: 6 months

    Freedom from Major Adverse Events (MAE): A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)

  2. Freedom from clinically driven target lesion revascularization (cd-TLR)

    Time frame: 12 months

    Any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.)

Secondary outcomes

  1. Freedom from clinically-driven target lesion revascularization (cd-TLR)

    Time frame: 6 and 24 months

  2. Freedom from clinically-driven target vessel revascularization (TVR)

    Time frame: 6, 12 and 24 months

  3. Primary patency

    Time frame: 12 and 24 months

    freedom from >50% restenosis in the target lesion as indicated by a duplex ultrasound peak systolic velocity ratio (PSVR) >2.5 or by visual assessment of an angiogram with no clinically driven re-intervention

  4. Freedom from Major Adverse Events (MAE)

    Time frame: 12 and 24 months

    Freedom from Major Adverse Events (MAE): A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)

  5. Change in mean Ankle Brachial Index (ABI)

    Time frame: 6, 12 and 24 months

    compared to the pre-procedure

  6. Improvement in Rutherford classification

    Time frame: 6, 12 and 24 months

    compared to the pre-procedure Rutherford classification

  7. Amputation-free survival (AFS)

    Time frame: 6, 12 and 24 months

    including major, minor and overall AFS

  8. Pain score

    Time frame: 6, 12 and 24 months

    compared to the pre-procedure score.

  9. Walking Impairment Questionnaire

    Time frame: 6, 12 and 24 months

    compared to the pre-procedure score.

  10. Device success

    Time frame: immediately upon index procedure

    Successful delivery, inflation, deflation, and retrieval of the Passeo-18 Lux DCB

  11. Technical success

    Time frame: immediately upon index procedure

    Successful completion of the endovascular procedure and immediate morphological success with ≤ 50% residual diameter reduction of the treated lesion as determined by visual estimation

  12. Procedural success

    Time frame: immediately upon discharge

    Procedural success is technical and device success without the occurrence of any MAE (as defined in the protocol) during the hospital stay

Sponsors and collaborators

Lead sponsor

Biotronik AG

Industry

Registry information

Official study title

BIOTRONIK - A Prospective, International, Multi-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Popliteal Arteries - III BENELUX

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Feb 14, 2017
Registry last updated
Aug 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.